- Home
- PMTS vs ELDN Comparison
PMTS vs ELDN Comparison
Compare PMTS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- ELDN
- Stock Information
- Founded
- PMTS 2007
- ELDN 2004
- Country
- PMTS United States
- ELDN United States
- Employees
- PMTS N/A
- ELDN N/A
- Industry
- PMTS Finance Companies
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- ELDN Health Care
- Exchange
- PMTS Nasdaq
- ELDN Nasdaq
- Market Cap
- PMTS 172.6M
- ELDN 202.4M
- IPO Year
- PMTS 2015
- ELDN N/A
- Fundamental
- Price
- PMTS $14.76
- ELDN $2.37
- Analyst Decision
- PMTS Strong Buy
- ELDN Strong Buy
- Analyst Count
- PMTS 4
- ELDN 2
- Target Price
- PMTS $34.00
- ELDN $12.50
- AVG Volume (30 Days)
- PMTS 35.1K
- ELDN 640.2K
- Earning Date
- PMTS 11-04-2025
- ELDN 11-11-2025
- Dividend Yield
- PMTS N/A
- ELDN N/A
- EPS Growth
- PMTS N/A
- ELDN N/A
- EPS
- PMTS 1.11
- ELDN 0.21
- Revenue
- PMTS $502,361,000.00
- ELDN N/A
- Revenue This Year
- PMTS $14.84
- ELDN N/A
- Revenue Next Year
- PMTS $10.55
- ELDN N/A
- P/E Ratio
- PMTS $13.44
- ELDN $11.10
- Revenue Growth
- PMTS 14.31
- ELDN N/A
- 52 Week Low
- PMTS $12.52
- ELDN $2.32
- 52 Week High
- PMTS $35.19
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- PMTS 41.71
- ELDN 35.17
- Support Level
- PMTS $13.82
- ELDN $2.41
- Resistance Level
- PMTS $15.42
- ELDN $2.84
- Average True Range (ATR)
- PMTS 0.74
- ELDN 0.13
- MACD
- PMTS 0.21
- ELDN 0.00
- Stochastic Oscillator
- PMTS 37.02
- ELDN 10.48
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.